updated 6/23/2011 7:16:01 AM ET 2011-06-23T11:16:01

DALLAS, June 23, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock report featuring Fibrocell Science Inc. (OTCBB:FCSC). The report details the company's recent developments and news, outlines its financial position, and recaps comparative and analyst consensus.

The full report is available at: www.microstockprofit.com/lp/FCSC

Fibrocell Science Inc. (FCSC) is a biotechnology company focused on the development of personalized autologous cell therapies for aesthetic, medical and scientific applications. The Company's clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient's own, or autologous, fibroblast cells produced by its proprietary Fibrocell process. Its clinical development programs encompass both aesthetic and therapeutic indications.

This newsletter has been helping traders make great investment decisions on FCSC; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares in the biotechnology company soared more than 54% yesterday on news that U.S. regulators have approved its smile lines wrinkle treatment laViv (azficel-T). FCSC said the patented technology behind laVív is an advanced process that extracts and multiplies a specific kind of a person's own skin cells (fibroblasts) to create laVív. The drug is then injected into the patient to improve the appearance of smile lines."

"The Company said that in clinical trials, laVív was well tolerated with the majority of adverse events being injection-site reactions that were of mild to moderate intensity and resolved within one week."

To read the entire report visit: www.microstockprofit.com/lp/FCSC

See what investors are saying about FCSC at http://www.stockhideout.com

Get breaking news on FCSC at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Jay Geller

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com